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INTRODUCTION
Peritoneal surface malignancy (PSM) refers to a group of conditions in which the intra-abdominal tumour spread is the dominant clinical picture. These include carcinomatosis of gastro-intestinal and gynecological origin and rare primary peritoneal tumours, such as peritoneal mesothelioma and the exceedingly uncommon primary peritoneal (extra-ovarian) carcinoma. [1] PSM were once regarded as endstage metastatic conditions only amenable to palliative options. Over the last two decades, these disease entities have been increasingly recognized as a manifestation of local-regional disease spread and, accordingly, an aggressive local-regional treatment approach has emerged. [1] This innovative strategy involves peritonectomy procedures and multivisceral resection to remove the macroscopic tumour, in combination with perioperative intraperitoneal chemotherapy to sterilize microscopic residual disease. [2] Several independent trials of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) have reported a dramatic survival improvement in selected patients with various PSM. [3] [4] [5] [6] [7] [8] Although pseudomyxoma peritonei is minimally aggressive, long-term survival after conventional debulking surgery and palliative chemotherapy was only 20-30%. With the advent of the local-regional approach, it has increased to 52-96%, and median survival to 51-156 months. [3] Analogously, median survival has improved from about 12 to 34-92 months for peritoneal mesothelioma and from 6 to 12-33 months for colorectal cancer carcinomatosis. [4] [5] In stage-III ovarian cancer, complete surgical cytoreduction has been shown to be closely related to survival and a phase-III study has demonstrated the survival benefit of intraperitoneal versus intravenous chemotherapy, supporting the use of the combined treatment in this clinical setting. [6] [7] [8] Results of cytoreduction and HIPEC in our Institution were reported previously: median survival was 41. 4 and 44 months for ovarian cancer and peritoneal mesothelioma, and 79.4% at ten years for pseudomyxoma peritonei. [9] [10] [11] Since the comprehensive approach was developed by Sugarbaker, many peritoneal malignancy treatment centres have been established in the USA, Japan, Australia and Europe. However, this treatment option is highly resource-expensive, requiring specialized surgical teams, complex technological facilities and long operative times. Although a few economic evaluations are available in the literature, costs have never been assessed in Italy, resulting in a slow diffusion of this technique in our country. Therefore, we have investigated the economic costs of cytoreduction and HIPEC in an Italian tertiary referral centre and compared costs with the reimbursement rates for these acts, according to the current diagnosis-related grouping (DRG) classification.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
4
MATERIALS AND METHODS
Study design
The economic evaluation was based on 382 procedures of cytoreduction and HIPEC performed in 376 patients by the same surgical team at the National Cancer Institute (NCI) in Milan (Italy) during the period 1995-2008. Milan NCI is a comprehensive cancer centre and the Italian reference institution for PSM management. The total cost of each hospital admission was assessed according to present day (2007) unit costs (e.g. cost of 1mg of chemotherapy agents, cost of one minute of operating room occupation). This methodology was applied to ensure both an updated economic evaluation and a larger database covering a wide spectrum of clinical settings. A comparison between the costs sustained and the financial support received in counterpart by our hospital was made for the last two years of the study period, when the number of procedures performed stabilized steadily at 35-40/year. Patient characteristics are shown in table 1.
Operative treatment
All patients included in this study were treated according to institutionally approved protocols with written informed consent. Eligibility requirements included: histological diagnosis of PSM; age ≤75; no relevant co-morbidities; Eastern Cooperative Oncology Group performance status ≤2; [12] no hepatic or distant metastasis; peritoneal disease amenable to complete/near-complete cytoreduction at preoperative computed tomography scan.
Cytoreductive surgery was based on the technique originally described by Sugarbaker, [2] with some modifications. [13] Briefly, the aim of the surgical cytoreduction was to remove all the visible peritoneal tumour by one to six of the following steps: right parietal peritonectomy ± right colectomy; pelvic and left parietal peritonectomy ± sigmoidectomy ± hystero-adnexectomy; lesser omentectomy and duodenal-hepatic ligament dissection ± cholecystectomy; right diaphragmatic peritonectomy ± Glisson's capsulectomy; greater omentectomy, left diaphragmatic peritonectomy ± splenectomy; gastric antrectomy/total gastrectomy ± other intestinal or abdominal mass resections. The extent of peritoneal involvement was rated at surgical exploration using the peritoneal cancer index (PCI). [14] M A N U S C R I P T
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The HIPEC was performed according to the closed-abdomen technique using two in-flow and two Following surgery, patients were admitted to the intensive care unit (ICU) to be continuously monitored. Laboratory and instrumental exams were performed daily. They were then discharged to the surgical ward for recovery. Laboratory exams were performed every three days until discharge.
Postoperative complications occurring during the hospital stay were rated according to the National Cancer Institute Common Terminology Criteria (http://ctep.cancer.gov/forms/CTCAEv3.pdf).
Cost assessment
Cost assessment focused on inpatient care. The activity based costing (ABC) methodology was applied to estimate hospital costs. [17] A detailed assessment of all expenditures in terms of materials used, drugs administered, pre-and postoperative examinations, professionals involved, equipment amortization, time spent in the operating theatre, days spent in ICU and surgical ward was carried out.
Information on patient and treatment characteristics, length of hospital and ICU stay, type and dosage of drugs administered during the HIPEC, blood product consumption were collected from a prospective clinical database specifically designed for patients with PSM. According to ABC principles, data on resource consumption were retrieved by detailed interviewees with medical and nurse staff. Costs of ancillaries and disposal materials were derived from tender adjudication prices. The remaining daily costs of hospitalization (i.e. daily costs of hospital bed occupancy), were provided by the Accounting Department as €200.00 for the surgical ward and €2,500.00 for the ICU. Once the mean cost of one hospital stay for cytoreduction and HIPEC was estimated, we conducted a sub-analysis according to a three-tiered classification of the complexity of the cytoreduction: level 1 (1-2 cytoreductive surgical procedures), level 2 (3-4 procedures) and level 3 (5-6 procedures).
Reimbursement rates
According to the official classification at the time of the study in Lombardia region, the stays for cytoreduction and HIPEC were categorized in two DRGs: -DRG 148: major small and large bowel surgical procedures, with complications (for whom our hospital received €9,632.70).
-DRG 408: poorly differentiated tumour undergoing major surgical procedures, with complications (for whom our hospital received €13,557.60).
RESULTS
Clinical data
The details of the combined procedures are displayed in table 2. Operative mortality occurred in 8 patient (2.1%), and grade 3/5 surgical complications in 70 (18.3%); reoperation rate was 50/382 (13.1%).
Bone-marrow toxicity occurred in 23 patients and renal toxicity in 22. Overall, 95 patients (24.8%) suffered of grade 3/5 adverse events.
The mean hospital stay was 24.3 days (range 9-108); in detail, median preoperative stay was one day (range 1-3), postoperative ICU stay 3 days (range 2-15) and surgical ward stay 18 days (range 7-91). 
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DISCUSSION
In the present analysis, the costs of the combined treatment of surgical cytoreduction and HIPEC were assessed in an Italian tertiary referral centre. Based on 382 consecutive procedures carried out in the period 1995-2008, the estimated mean cost for one procedure was €36,015.89. As compared with the financial support received by our hospital, this resulted in an economic deficit of approximately €1,850,000 for the last two years.
The main criticism against cytoreduction and HIPEC is that long-term survival has been achieved in selected case-series and modern chemotherapeutic and biologic agents for metastatic colo-rectal cancer might obtain comparable results in the same patients. [18] However, these drugs have never been thoroughly assessed by medical oncologists in the setting of peritoneal carcinomatosis. Furthermore, two comparative surgical studies have demonstrated the superiority of cytoreduction and HIPEC over conventional treatment: in a randomized trial, median survival was 23 months with the combined approach and 12.6 months with fluorouracil/leucovorin-based systemic chemotherapy (P=0.0032). [19] In a recent retrospective controlled study, median survival was 23.9 months with modern systemic agents and an unprecedented 62.7 months with optimal cytoreduction and HIPEC (P<0.05). [20] Additionally, the combined treatment has been questioned for its high complications rates, but a recent comprehensive literature review demonstrated that morbidity and mortality are comparable with major abdominal surgery. [21] Criticisms have also involved the high economic cost of combined treatment. However, the Institut Gustave-Roussy (Villejuif, France) estimated in a retrospective controlled study the cost-effectiveness of HIPEC versus systemic chemotherapy for colo-rectal cancer carcinomatosis as €58,086 per life-year saved (95% confidence interval 35,893-112,839). [22] In comparison, the cost of one life-year saved is €75,000-146,000 for imatinib in unresectable gastro-intestinal stromal tumour (versus supportive care) and €103,000-120,000 for trastuzumab in metastatic breast cancer (versus standard chemotherapy). [23] [24] Despite these important advancements, a peritoneal malignancy project in Italy does not receive an adequate financial support. Our current DRG classification does not include this procedure, resulting in a heavy economic deficit for the hospitals accepting the responsibility of treating these patients. Although our analysis is related to the Italian setting, information were provided which may improve the diffusion of the combined treatment in other tax-founded health systems, like in most European countries. As DRGs are M A N U S C R I P T
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updated periodically, a thorough cost assessment is the first step to obtain reimbursement rates adequate to the real cost of the procedure. An alternative solution, adopted by centres in the Netherlands and England, may be to negotiate a contract with the health authorities to finance specific cares not covered by the DRG system. [25] [26] Any method of reimbursement, however, should take into the consideration that the procedure consists in a combination of surgical acts with the HIPEC. Our economic analysis demonstrated that final costs are closely related to the extent of the surgical efforts. Therefore, it seems rational to establish a total act with three different definitions: peritoneal and visceral cytoreductive surgery associated with HIPEC for peritoneal malignancy, of low, intermediate or high complexity.
Cytoreduction and HIPEC is an innovative therapy and economic evaluation are lacking. In 1996, Sugarbaker reported a total cost of the procedure of USD166,922 (range 72,795-185,464) (€116,950; range 50,760-129,324), based on 25 cases of pseudomyxoma peritonei. [27] However, this study was specific to the insurance-based USA health system and charge data were used to simulate costs, being of limited value for most European countries. The American study, together with UK price data and expert advices, was used to set a Monte-Carlo simulation model to estimate the marginal cost of the combined procedure for pseudomyxoma peritonei in the UK. The estimated cost for one patient over 5 years was 9,717 pounds (€10,907), with a standard deviation (SD) of 1,284 pounds (€1,441). [28] These results contrast with those of the US study, since the total amount was about one tenth of the American costs, although the studies are scarcely comparable, due to differences in the provision of the specific service. As a matter of fact, it has been recently reported that the Basingstoke Centre receive from the National Health Service 75,000 pounds per case, covering outpatient assessment, surgical treatment, follow-up and research. [19] In France, the cost of cytoreductive surgery with HIPEC was evaluated in 73 patients treated for for pseudomyxoma peritonei (€59,482). Based on available data on lifetime cost for colorectal cancer carcinomatosis managed with palliative therapies, the cost per life-year saved with cytoreduction and HIPEC ranged from AUD20,521 (€13,223) for peritoneal mesothelioma to AUD29,599 (€19,073) for pseudomyxoma peritonei. [29] In the present study, economic costs were assessed according to the methodology of activity-based costing. [16] Unlike conventional costing accountancy in hospitals, which mainly focuses on services, the ABC approach focuses on activities, assuming that activities consume resources and services consume the activities. The ABC allows costs to be assessed thoroughly and correctly, since the resources used and activities performed are described precisely. Furthermore, it assigns more indirect costs into direct costs.
Despite these advantages, ABC is still used in few hospitals because such a methodology is more expensive and time-consuming and requires more data than traditional costing approaches. [30] These potential drawbacks, however, were overcome by taking advantage of our prospective and exhaustive clinical database.
Some limitations of the present study must be mentioned. First, our analysis focused on inpatient care and omitted ambulatory and indirect costs, because these information were difficult to collect retrospectively. [28] The severity of PSM implies that most outpatient and inpatient care was given by highly specialized institutions and ambulatory costs can be assumed to be marginal. Second, the study did not included the costs of establishing a peritoneal malignancy management centre, such as training teams, although specialist equipment amortization was taken into account. [26] Third, additional costs for subsequent hospital stays related to HIPEC procedure, such as interventions for stoma closure, rehabilitation, disease recurrence or delayed treatment consequences, were not considered.
In conclusion, although clinical results from our and other centres demonstrate safety and efficacy of cytoreduction and HIPEC in the management of selected cases of PSM, the Italian current DRG classification does not include this therapy. Consequently, the hospitals offering this treatment option to their patients receive in counterpart an inadequate financial support. Necessary corrective measures are to include this procedure in the official list of medical acts, and to determine its specific cost for reimbursing. 
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